Skip to main content
HCPCS J0688 · Level II · Part B drug

J0688: cefazolin sodium, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0688

Billing unit
500 MG
Inj cefazolin sodium, hikma
ASP payment limit
$0.829
October 2026; -2.1% vs July 2026
Practitioner MUE
16
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J0688 is the Level II code for Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg, billed per 500 MG. The Medicare Part B ASP payment limit for October 2026 is $0.829 per billing unit, down 2.1% from July 2026. The practitioner MUE allows up to 16 units per date of service (MAI 3), so a full 16-unit day is $13.26 at the current limit. Under OPPS it carries status indicator N. J0688 is billed in units of 500 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names cefazolin sodium: J0687 (the WG Critical Care product (manufacturer named in its CMS descriptor)); J0689 (the Baxter product (manufacturer named in its CMS descriptor)); J0690 (the code whose CMS descriptor names no specific product). The ASP crosswalk maps 2 NDCs to it, sold as Cefazolin Sodium by Hikma Pharmaceuticals USA Inc. No current Billing and Coding Article lists J0688, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0688 at $0.829 per 500 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.847 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J0688
QuarterPayment limitPerCoinsurance
October 2026$0.829500 MG20%
July 2026$0.847500 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J0688. Report the NDC in the claim's drug segment and bill the number of J0688 units that equals the quantity administered divided by 500 MG; the last column gives units per full package.

NDCs that crosswalk to J0688
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9139-25Cefazolin SodiumHikma Pharmaceuticals USA Inc.1 × 25100
00143-9140-25Cefazolin SodiumHikma Pharmaceuticals USA Inc.1 × 25150

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J0688. For practitioners the limit is 16 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J0688 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services163 Date of Service Edit: ClinicalCMS Policy
Facility outpatient hospital163 Date of Service Edit: ClinicalCMS Policy
DME supplier163 Date of Service Edit: ClinicalCMS Policy

MUE for J0688 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0688 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0688 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0688 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J0688 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0688 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0688 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J0688 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0688

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0688

What does HCPCS code J0688 describe?

J0688 is defined by CMS as "Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg". Each billing unit represents 500 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J0688 a CPT code?

No. J0688 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as cefazolin sodium; CPT codes are five-character codes maintained by the AMA. On a Part B claim J0688 reports the drug itself in 500 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0688 in October 2026?

The ASP-based payment limit is $0.829 per 500 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.847. Commercial payers use their own fee schedules.

How many units of J0688 can be billed per day?

The practitioner Medically Unlikely Edit is 16 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "CMS Policy" as the rationale.

Which NDCs map to J0688?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Cefazolin Sodium (Hikma Pharmaceuticals USA Inc.). For example NDC 00143-9139-25 (package size 1) equals 100 billing units of J0688.

Does J0688 have NCCI bundling edits?

No active practitioner PTP pairs list J0688 as a column-1 or column-2 code in the v323r0 release.

J0688 vs J0687: what is the difference?

Both are HCPCS Level II codes whose descriptor names cefazolin sodium. What sets J0687 apart: the WG Critical Care product (manufacturer named in its CMS descriptor). J0688 is billed per 500 mg, limit $0.829, MUE 16; J0687 is billed per 500 mg, limit $0.663, MUE 16. Report the code whose descriptor matches the product and setting in the record.

J0688 vs J0689: what is the difference?

Both are HCPCS Level II codes whose descriptor names cefazolin sodium. What sets J0689 apart: the Baxter product (manufacturer named in its CMS descriptor). J0688 is billed per 500 mg, limit $0.829, MUE 16; J0689 is billed per 500 mg, limit $1.281, MUE 16. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.